-
公开(公告)号:US11136364B2
公开(公告)日:2021-10-05
申请号:US15768865
申请日:2016-10-28
申请人: YUHAN CORPORATION
发明人: Jun Hwan Kim , Seyoung Lim , Minji Seo , Hyun Ho Choi , Dohoon Kim , Mi Kyeong Ju , Ju-Young Park , Seul Gi Kim , Sangmyoun Lim , Jong Gyun Kim , Su Youn Nam
IPC分类号: A61K38/18 , C07K14/50 , C07K14/575 , C07K14/605
摘要: The present invention provides a dual function protein prepared by linking a biologically active protein and an FGF mutant protein to an Fc region of an immunoglobulin, which has improved pharmacological efficacy, in vivo duration and protein stability. A dual function protein according to the present invention exhibits improved pharmacological efficacy, in vivo duration and protein stability, and a pharmaceutical composition containing the dual function protein as an active ingredient may be effectively used as a therapeutic agent for diabetes, obesity, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis or cardiovascular diseases.
-
公开(公告)号:US20190153055A1
公开(公告)日:2019-05-23
申请号:US16097572
申请日:2017-04-19
申请人: YUHAN CORPORATION
发明人: Su Youn Nam , Jong Gyun Kim , Byung Hyun Choi , June Hyung Lee , Ju Young Park , Jun Kyung Lee , Na Rae Lee , Ki Hong Kim , Seul Gi Kim , Se Woong Oh , Seung Yub Shin , Ho Woong Kang , Su Jin Ahn , Soo Yong Chung
摘要: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.
-
公开(公告)号:US11046742B2
公开(公告)日:2021-06-29
申请号:US16097572
申请日:2017-04-19
申请人: YUHAN CORPORATION
发明人: Su Youn Nam , Jong Gyun Kim , Byung Hyun Choi , June Hyung Lee , Ju Young Park , Jun Kyung Lee , Na Rae Lee , Ki Hong Kim , Seul Gi Kim , Se Woong Oh , Seung Yub Shin , Ho Woong Kang , Su Jin Ahn , Soo Yong Chung
IPC分类号: C07K14/52 , C07K19/00 , C12N15/09 , C12N15/11 , C12N15/63 , A61K38/19 , A61K47/68 , A61P35/00 , A61K38/00 , A61K47/50
摘要: Provided are a fusion protein having a CCL3 variant with improved in vivo persistency, protein stability and pharmacological activity and a use thereof, more particularly, a fusion protein comprising a CCL3 variant and an immunoglobulin Fc region and a use thereof as a therapeutic agent for lymphopenia, cancer or infection, in which an N-terminal amino acid of a wild-type CCL3α or CCL3β is deleted and an amino acid at a specific position is substituted with a different amino acid at the same position of the wild-type CCL3α or CCL3β in the CCL3 variant.
-
-